Justin Toups, MD
Gastroenterology · Thibodaux, LANPI 1780877431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,772 of the $23,578 with a category attached, or 71.1%. Madrigal Pharmaceuticals accounts for 78.5% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $12,508, more than ten times the $970 reported in 2019.
Across 378 payments — averaging $62.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$19K
- Gilead$1K
- AbbVie$1K
- Bristol Myers Squibb$411
- Takeda Pharmaceuticals U.S.A., Inc.$348
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$285
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$16,77271%
- Travel & lodging$6663%
- Food & beverage$6,12526%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 36 | $18,502 |
| Gilead | 72 | $1,215 |
| AbbVie(2 entities) | 103 | $1,118 |
| Bristol Myers Squibb | 26 | $411 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $348 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $285 |
| Johnson & Johnson | 16 | $246 |
| Redhill Biopharma Inc. | 15 | $213 |
| Ironwood Pharmaceuticals, Inc | 12 | $209 |
| Pfizer | 9 | $149 |
| Sanofi | 7 | $143 |
| Romark Laboratories, LC | 8 | $136 |
| Covidien LP | 1 | $77 |
| Celltrion USA Inc. | 3 | $63 |
| Braintree Laboratories, Inc. | 3 | $51 |
| Intercept Pharmaceuticals, Inc. | 3 | $49 |
| Ardelyx, Inc. | 2 | $48 |
| Concordia Pharmaceuticals Inc. | 2 | $45 |
| QOL Medical, LLC | 2 | $36 |
| Abbott | 1 | $28 |
| Boehringer Ingelheim | 2 | $27 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| Axonics, Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Amgen | 1 | $16 |
| Evoke Pharma, Inc. | 1 | $14 |
| Organon | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$17,764
How this compares
$23,578 in reported general payments places this provider in the 85th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 21 | $548,049 |
| Humira(Cf) PenAdalimumab | 23 | $155,212 |
| LinzessLinaclotide | 72 | $51,841 |
| XifaxanRifaximin | 14 | $43,352 |
| ViberziEluxadoline | 12 | $16,759 |
| TrulancePlecanatide | 29 | $16,545 |
| MotegrityPrucalopride Succinate | 29 | $15,140 |
| Colestipol Hcl | 184 | $10,882 |
| Pantoprazole Sodium | 970 | $9,604 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 47 | $7,857 |
| Sucralfate | 94 | $6,840 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 43 | $5,852 |
| Omeprazole | 271 | $3,999 |
| Balsalazide Disodium | 28 | $3,336 |
| Esomeprazole Magnesium | 131 | $3,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $246 | $548,04921 claims |
| AbbVieLinzess, Viberzi | $1,118 | $68,60084 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $285 | $65,74986 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $348 | $15,14029 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $27 | $7,85747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Thibodaux
- Charles MonierThibodaux$448K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
- Humberto AguilarShreveport$313K
- Sarah GloverNew Orleans$274K
- Nisha LoganantharajNew Orleans$173K
- Shamita ShahNew Orleans$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.